**8. References**


Recent Advances in the Treatment of Neurological Autoimmune Disorders 311

Buckley, C. & Vincent, A. (2005). Autoimmune Channelopathies. *Nature Clin Pract Neurol*,

Bufler, J., Kahlert, S., Tzartos, S., Toyka, K.V., Maelicke, A. & Franke, C. (1996). Activation

Cepok, S., Rosche., Grummel, V., Vogel, F., Zhou, D., Sayn, J., Sommer,N., Hartung, H.P. &

Charo, I.F. & Ransohoff, R.M. (2006). The many roles of chemokines and chemokine

Chatenoud, L. (2003). CD3-specific antibody-induced active tolerance:from bench to

Cheung, C.H., Chen, H.H., Cheng, L.T., Lyu, K.W., Kanwar, J.R. & Chang, J.Y. (2010).

Cheung, C.H., Sun, X., Kanwar, J.R., Bai, J.Z., Cheng, L. & Krissansen, G.W. (2010b). A cell-

prostate cancer cells to TNF-α therapy. *Cancer Cell Int*, Vol.1, No.10, pp. 36. Clancy, R.M., Backer, C.B., Yin, X., Chang, M.W., Cohen, S.R. & Lee, L.A. (2004a). Genetic

Clerico, M., Contessa, G. & Durelli, L. (2007). Interferon-beta1a for the treatment of multiple

Clifford, D.B., De Luca, A., Simpson, D.M., Arendt, G., Giovannoni, G. & Nath, A. (2010).

Cooper, G.S., Dooley, M.A., Treadwell, E.L., St Clair, E.W. & Gilkeson, G.S. (2002).

binding site of the acetylcholine receptor. *J Physiol*, Vol.492, pp. 107-114. Cappione, A., Anolik, J.H., Pugh-Bernard, A., Barnard, J., Dutcher, P., Silverman, G. & Sanz,

systemic lupus erythematosus. *J. Clin. Invest,* Vol.115, pp. 3205–3216. Carpentier, A.F. & Delattre, J.Y. (2001). The Lambert-Eaton myasthenic syndrome, *Clin Rev* 

during the course of multiple sclerosis. *Brain*, Vol.128, pp. 1667–1676. Chan, A., Weilbach, F.X., Toyka, K.V. & Gold, R. (2005). Mitoxantrone induces cell death in

receptors in inflammation. *N. Engl. J. Med*, Vol.354, pp. 610–621.

bedside. *Nat. Rev. Immunol*, Vol.3, pp. 123–132.

heart block. *Arthritis Rheum,* Vol.50, pp. 173–182.

sclerosis. *Expert Opin Biol Ther*, Vol.7, No.4, pp. 535–542.

multiple sclerosis patients. *J Immunol*, Vol.164, pp. 2782–2789.

*Mol Cancer*, Vol.15, No.9, pp. 77.

487-494.

Vol.1, pp. 22–32.

Vol.139, pp. 152-158.

*Allergy Immunol,* Vol.20, pp. 155–158.

neutralization by intravenous immunoglobulins. *Muscle Nerve,* Vol.31, No.4, pp.

and blockade of mouse muscle nicotinic channels by antibodies directed against the

I. (2005). Germinal center exclusion of autoreactive B cells is defective in human

Hemmer, B. (2005). Short-lived plasma blasts are the main B cell effector subset

peripheral blood leucocytes of multiple sclerosis patients. *Clin Exp Immunol*,

Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells.

permeable dominant-negative survivin protein induces apoptosis and sensitizes

association of cutaneous neonatal lupus with HLA class II and tumor necrosis factor alpha: implications for pathogenesis. *Arthritis Rheum,* Vol.50, pp. 2598–2603. Clancy, R.M., Kapur, R.P., Molad, Y., Askanase, A.D. & Buyon, J.P. (2004b).

Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital

Natalizumabassociated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. *Lancet Neurol, Vol*.9, pp. 438–446. Colombo, M., Dono, M., Gazzola, P., Roncella, S., Valetto, A. & Chiorazzi, N. (2000).

Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of

Hormonal and reproductive risk factors for development of systemic lupus


Baker, K.P., Edwards, B.M., Main, S.H., Choi, G.H., Wager, R.E. & Halpern, W.G. (2003).

Baranzini, S. E., Jeong, M. C., Butunoi, C., Murray, R. S., Bernard, C. C. & Oksenberg, J. R.

Baratchi, S., Kanwar, R.K., Cheung, C.H. & Kanwar, J.R. (2010a). Proliferative and protective

Baratchi, S., Kanwar, R.K. & Kanwar, J.R. (2010b). Survivin: a target from brain cancer to neurodegenerative disease. *Crit Rev Biochem Mol Biol*, Vol.45, No.6, pp. 535-554. Baratchi, S., Kanwar, R.K. & Kanwar, J.R. (2011a). Novel survivin mutant protects

Baratchi, S., Kanwar, R.K. & Kanwar, J.R. (2011b). Survivin mutant protects differentiated

Barzilai, O., Ram, M. & Shoenfeld, Y. ( 2007a). Viral infection can induce the production of

Barzilai, O., Sherer, Y., Ram, M., Izhaky, D.,Anaya, J.M. & Shoenfeld, Y. (2007b). Epstein-

Begovich, A.B., Carlton, V.E., Honigberg, L.A., Schrodi, S.J. & Chokkalingam, A.P. (2004).

Bergamaschi, R. (2007).Immune agents for the treatment of Devic's neuromyelitis optica.

Bottini, N., Musumeci, L., Alonso, A., Rahmouni, S. & Nika, K. (2004). A functional variant

Bishop, G.A., Haxhinasto, S.A., Stunz, L.L. & Hostager, B.S. (2003). Antigen-specific B-

Bretscher, P. & Cohn, M. A. (1970). Theory of self-nonself discrimination. *Science,* Vol.169,

Bjorksten, B. (1994). Risk factors in early childhood for the development of allergic disease.

Bondanza, A., Zimmermann, V.S., Antonio, G.D., Cin, E.D., Balestrieri, G., Tincani, A.,

Buchwald, B., Ahangari, R., Weishaupt, A. & Toyka, K.V. (2005). Presynaptic effects of

Amoura, Z., Piette, J.C., Sabbadini, M.G., Querini, P.R. & Manfred, A.A. (2004). Requirement of Dying Cells and Environmental Adjuvants for the Induction of Autoimmunity. *ARTHRITIS & RHEUMATISM,* Vol.50, No. 5, pp. 1549–1560. Brosnan, C.F. & Raine, C.S, (1996). Mechanisms of immune injury in multiple sclerosis. *Brain* 

immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: their

neurotoxicity. *J Neuroimmunol*, Vol.233, No.1-2, pp. 18-28.

autoantibodies. *Curr Opin Rheumatol,* Vol.19, pp. 636–643.

A preliminary report. *Ann N Y Acad Sci*, Vol.1108, pp. 567–577.

lymphocyte activation. *Crit. Rev. Immunol,* Vol.23, pp. 149–197.

Vol.48, pp. 3253–3265.

pp. 120-32.

e15865.

Vol.75, pp. 330–337.

Vol.36, pp. 337–338.

pp. 1042-1049.

*Neurol Sci* , Vol.28, pp. 238–240.

*Allergy*, Vol.49, pp. 400-407.

*Pathol,* Vol.6, pp. 243–257.

lesions. *J Immunol*, Vol.163, pp. 5133–5144.

Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. *Arthritis Rheum*,

(1999). B cell repertoire diversity and clonal expansion in multiple sclerosis brain

effects of SurR9-C84A on differentiated neural cells. *J Neuroimmunol*, Vol.8, No.227,

differentiated SK-N-SH human neuroblastoma cells from activated T-cell

dopaminergic SK-N-SH cells against oxidative stress. *PLoS One,* Vol.10, No.6, pp.

Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious?

Amissense singlenucleotide polymorphism in a gene encoding a protein tyrosine phos,phatase (PTPN22) is associated with rheumatoid arthritis. *Am. J. Hum. Genet*,

of lymphoid tyrosine phosphatase is associated with type I diabetes. *Nat. Genet,* 

neutralization by intravenous immunoglobulins. *Muscle Nerve,* Vol.31, No.4, pp. 487-494.


erythematosus: results of a population-based, casecontrol study. *Arthritis Rheum*, Vol.46, pp. 1830–1839.

Recent Advances in the Treatment of Neurological Autoimmune Disorders 313

Duddy, M.E. & Baker, M.R. (2009). Stiff person syndrome. *Front Neurol Neurosci*, Vol.26, pp.

Fang, C., Zhang, X., Miwa, T. & Song, W.C. (2009). Complement promotes the development

of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production. *Blood*, Vol.114, pp. 1005–1015. Faraco, G., Cavone, L. & Chiarugi, A. (2011). The Therapeutic Potential of HDAC Inhibitors in the Treatment of Multiple Sclerosis. *Mol Med*. Feb 25. [Epub ahead of print]. Fauci, A.S., Wolff, S.M. & Johnson, J.S. (1971). Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis, *N Engl J Med,* Vol.285, pp. 1493-1496. Flickinger, C.J., Baran, M.L., Howards, S.S. & Herr, J.C. (1994). Epididymal obstruction

during development results in antisperm autoantibodies at puberty in rats. *J* 

autoantigen translocation and autoantibody opsonization lead to increased dendritic cell phagocytosis and presentation of nuclear antigens: a novel

Fraga, A., Mintz, G. & Orozco, J. (1974). Sterility and fertility rates, fetal wastage and

Frisoni, L., McPhie, L., Colonna, L., Sriram, U., Monestier, M. & Gallucci, S. (2005). Nuclear

pathogenic pathway for autoimmunity? *J Immunol*, Vol.175, pp. 2692–2701. Frohman, E.M., Racke, M.K. & Raine, C.S. (2006). Multiple sclerosis-the plaque and its

Fugger, L., Friese, M.A. & Bell, J.I. (2009). From genes to function: The next challenge to understanding multiple sclerosis. *Nat Rev Immunol*, Vol.9, No.6, pp. 408–417. Fujinami, R.S. & Oldstone, M.B. (1989). Molecular mimicry as a mechanism for virus-

Fujinami, R.S.& Oldstone, M.B. (1985). Amino acid homology between the encephalitogenic

Gabriel, C.L., Wu, L., Parekh, V.V. & Van Kaer, L. (2010). Invariant natural killer t cell-based

Gehrs, B.C. & Friedberg, R.C. (2002). Autoimmune hemolytic anemia. *Am J Hematol,* Vol.69,

Gellert, M. (2002). V(D)J recombination: RAG proteins, repair factors, and regulation. *Annu.* 

Genovese, M.C., Kaine, J.L., Lowenstein, M.B., Del Giudice, J., Baldassare, A., Schechtman,

Gold, R., Dalakas, M.C. & Toyka, K.V. (2003). Immunotherapy in autoimmune

Gold, R., Linington, C. & Lassmann, H. (2006). Understanding pathogenesis and therapy of

neuromuscular disorders. *Lancet Neurol,* Vol.2, pp. 22-32.

site of myelin basic protein and virus: mechanism for autoimmunity. *Science*,

therapy of autoimmune diseases. *Current Immunology Reviews*, Vol.6, No.2, pp. 88-

J., Fudman, E., Kohen, M., Gujrathi, S., Trapp, R.G., Sweiss, N.J., Spaniolo, G. & Dummer, W. (2008). Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. *Arthritis Rheum*, Vol.58, No.9, pp.

multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. *Brain,* Vol.129, pp. 1953–

maternal morbidity in SLE. *J. Rheumatol*, Vol.1*,* pp. 293–298.

pathogenesis. *N. Engl. J. Med*, Vol.354, pp. 942–955.

induced autoimmunity. *Immunol Res*, Vol.8, pp. 3-15.

147-165.

*Androl,* Vol.19, pp. 136-144.

Vol.230,No.4729, pp. 1043-1045.

*Rev. Biochem,* Vol*.71*, pp. 101–132.

101.

pp. 258–271.

2652-2661.

1971.


Crow, M.K. (2004). Costimulatory molecules and T-cell–B-cell interactions. *Rheum. Dis. Clin.* 

Cutolo, M. & Accardo, S. (1991). Sex hormones and rheumatoid arthritis. *Clin. Exp.* 

Cutolo, M. (2003). Solar light effects on onset/relapses and circannual/circadian symptomatology in rheumatoid arthritis. *Clin Exp Rheumatol,*Vol.21, pp. 148–150. Czaplinski, & Steck, A.J. (2004). Immune mediated neuropathies: an update on therapeutic

Dalakas, M.C. & Quarles, R.H. (1996). Autoimmune ataxic Neuropathies (sensory

Dalakas, M.C. (1999). Intravenous immunoglobulin in the treatment of autoimmune

Dalakas, M.C., Fujii, M., Li, M. & McElroy, B. (2000). The clinical spectrum of anti-GAD

Dalakas, M.C., Li, M., Fujii, M. & Jacobowitz, D.M. (2001). Stiff-person syndrome:

Dalakas, M.C. (2006). B cells in the pathophysiology of autoimmune neurological disorders:

Dalakas, M.C. (2008). B cells as therapeutic targets in autoimmune neurological disorders.

*Dalakas, M.C. (2009). Stiff person syndrome: advances in pathogenesis and therapeutic* 

Dalmau, F., Graus, M.K., Rosenblum, & Posner, J.B. (1992). Anti-Hu-associated

Damian, R.T. (1964). Molecular mimicry: antigen sharing by parasite and host and its

Darnell, R.B. & Posner, J.B. (2003). Paraneoplastic syndromes involving the nervous system,

Davidson, A. & Diamond, B. (2001). Advances in Immunology. *N Engl J Med*, Vol. 345, No. 5,

Dedrick, R.L., Bodary, S. & Garovoy, M.R. (2003). Adhesion molecules as therapeutic targets

Delves, P.J. (2006). Structural and functional aspects of the innate and adaptive systems of

Druet, P. (1989). Contributions of immunological reactions to nephrotoxicity. *Toxicol Lett*,

Drachman, D.B. (1994). Myasthenia gravis, *N Engl J Med,* Vol.330, pp. 1797–1810.

for autoimmune diseases and transplant rejection. Expert Opin Biol Ther, Vol.3,

immunity. In: Rose, NR and Mackay, IR, (eds.) *The autoimmune diseases*. pp. 9-21.

*interventions.* Curr Treat Options Neurol*,* Vol.11, No.2, pp*. 102-110.* 

ganglionopathies): are glycolipids the responsible autoantigens?. *Ann Neurol,*

neuromuscular diseases: present status and practical therapeutic guidelines. *Muscle* 

antibody-positive patients with stiff-person syndrome. *Neurology,* Vol.55, pp. 1531–

quantification, specificity and intrathecal synthesis of GAD65 antibodies. *Neurology,*

A credible therapeutic target. *Pharmacology & Therapeutics*, Vol.112, No.1, pp. 57-70.

paraneoplastic encephalomyelitis/sensory neuropathy: a clinical study of 71

Vol.46, pp. 1830–1839.

Vol39, pp. 419–422.

Vol.57, pp. 780–785.

pp. 340-350.

No.1, pp. 85-95.

Elsevier: San Diego.

Vol.46 pp. 55-64.

1535.

*North Am,* Vol*.*30, pp. 175–191.

*Rheumatol*, Vol.9, pp. 641–646.

strategies. *J Neurol*, Vol.251, pp. 127–137.

*Nerve*, Vol.22, No.11, pp. 1479-1497.

*Nat Clin Pract Neurol*, Vol.4, No.10, pp. 557-567.

patients. *Medicine (Baltimore),* Vol.71, pp. 59–72.

*N Engl J Med*, Vol.349, pp. 1543–1554.

consequences. *Am. Naturalist,* Vol.XCVIII, pp. 129–149.

erythematosus: results of a population-based, casecontrol study. *Arthritis Rheum*,


Recent Advances in the Treatment of Neurological Autoimmune Disorders 315

Hohlfeld, R., Melms, A., Schneider, C., Toyka, K.V. & Drachman, D.B. (2003). Therapy of

Holmes, C.H. & Simpson, K.L. (1992). Complement and pregnancy. New insights into the

Hooks, J.J., Jordan, G.W., Cupps, T., Moutsopoulos, H.M., Fauci, A.S. & Notkins, A.L..

Hoyer, B.F., Moser, K., Hauser, A.E., Peddinghaus, A., Voigt, C., Eilat, D., Radbruch, A.,

Ishii, A. (2010). Stiff-person syndrome and other myelopathies constitute paraneoplastic

Jacobson, D.L. (1997). Epidemiology and estimated population burden of selected

Janeway, C. Jr. & Travers, P. (1998) Immunobiology. In: *The Immune System in Health and* 

Johnson, P.M. (1993). Reproductive and maternofetal relations, In: Gell, P.G.H. & Coombs, R.R.A, *Clinical Aspects of Immunology*, Blackwell Johnson, Oxford, pp. 755–767. Kanwar, J.R., Harrison, J.E.B., Wang, D., Leung, E., Mueller, W., Wagner, N. & Krissansen,

Kanwar, J.R., Kanwar, R.K., Wang, D. & Krissansen, G.W. (2000). Prevention of a chronic

Kanwar, J.R., Berg, R.W., Yang, Y., Kanwar, R.K., Ching, L.M., Sun, X. & Krissansen, G.W.

Kanwar, J.R., Kanwar, R.K. & Krissansen, G.W. (2004). Simultaneous neuroprotection and

Kanwar. J.R. (2005). Anti-inflammatory immunotherapy for multiple sclerosis/experimental

system*. Journal of Neuroimmunology*, Vol.103, No.2000, pp. 146–152.

disease progression. *Immunology and Cell Biology,* Vol.78, pp. 641–645. Kanwar, R.K., Kanwar, J.R., Wang, D., Ormrod, D.J. & Krissansen, G.W. (2001). Temporal

*Thromb Vasc Biol*, Vol.21, pp. 1991-1997.

*Ther*, Vol.10, No.6, pp. 468-476.

No.6, pp. 131313-131331.

2947-2962.

erythematosus and vasculitis. *Arthritis Rheum,* Vol.25, pp. 396-400.

neurological syndromes. *Brain Nerve*, Vol.62, No.4, pp. 377-385.

Elsevier, Stuttgart, pp. 1341-1362.

*Gynecol,*Vol.6, pp.(439–460).

pp. 1577–1584.

223-243.

524.

myasthenia gravis and myasthenic syndromes. Brandt, T., Caplan, L.R., Dichgans, J., Diener, H.C. & Kennard, C. In: *Neurological disorders: course and treatment,*

immunobiology of the feto maternal relationship. *Ballières Clin. Obstet.* 

(1982). Multiple interferons in the circulation of patients with systemic lupus

Manz, R.A. & Hiepe, F. (2004). Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/w mice. *J. Exp.Med*, Vol.199,

autoimmune disease in the United States. *Clin Immunol Immunopathol,* Vol.84, pp.

*Disease,* pp 625-640. Garland Publishing Inc, New York Jarow, J.P., Goluboff, E.T., Chang, T.S. & Marshall, F.F. (1994). Relationship between antisperm antibodies and testicular histologic changes in humans after vasectomy. *Urology,* Vol.43, pp. 521-

G.W. (1999). β7 integrins contribute to demyelinating disease of the central nervous

progressive form of experimental autoimmune encephalomyelitis by an antibody against mucosal addressin cell adhesion molecule-1, given early in the course of

Expression of Heat Shock Proteins 60 and 70 at Lesion-Prone Sites. *Arterioscler* 

(2003). Requirements for ICAM-1 immunogene therapy of lymphoma. *Cancer Gene* 

blockade of inflammation reverses autoimmune encephalomyelitis. *Brain*, Vol.127,

autoimmune encephalomyelitis (EAE) disease. *Curr Med Chem*, Vol.12, No.25, pp.


Goldrath, A.W. & Bevan, M.J. (1999). Selecting and maintaining a diverse T-cell repertoire.

Graus, F., Keime-Guibert, F., Rene, R., Benyahia, B., Ribalta, T. & Ascaso, C. (2001). Anti-

Green, A.J., McQuaid, S., Hauser, S.L., Allen I.V. & Lyness, R. (2010). Ocular pathology in

Greter, M., Heppner, F.L., Lemos, M.P., Odermatt, B.M., Goebels, N., Laufer, T., Noelle, R.J.

Gu, H., Tarlinton, D., Muller, W., Rajewsky, K. & Forster, I. (1991). Most peripheral B cells in

Hadden, R.D., Cornblath, D.R., Hughes RA., Zielasek, J., Hartung, H.P., Toyka, K.V. &

Hafer-Macko, C. E., Sheikh, K. A., Li, C. Y., Ho, T. W., Cornblath, D. R. & McKhann, G. M..

Hauser, S.L. (2008). Multiple lessons for multiple sclerosis. *N Engl J Med*, Vol.359, No.17, pp.

Hauser, S.L., Waubant, E., Arnold, D.L., Vollmer, T., Antel, J., Fox, R.J., Bar-Or, A., Panzara,

Hayashi, A., Nakamagoe, K., Ohkoshi, N., Hoshino, S. & Shoji, S. (1999). Double filtration

Hennies, C., Sternberg, D., Bistulfi, G.L., Kazim, L., Benedict, R.H.B., Chadha, K., Leung, C.,

Heppner, F.L., Greter, M., Marino, D., Falsig, J., Raivich, G., Hovelmeyer, N., Waisman, A.,

Herrmann, M., Sholmerich, J. & Straub, R.H. (2000). Stress and rheumatic disease. *Rheum Dis* 

Hickey, W. F., Hsu, B. L. & Kimura, H. (1991). T-lymphocyte entry into the central nervous

Hodgkin, P.D. & Basten, A.B. (1995). Cell activation, tolerance and antigenpresenting

with negative anti-GAD antibody. *J Med*, Vol.30, No.(5-6), pp. 321-327. Heather Rachel Davids, (Mar, 2010), Guillain-Barre Syndrome: Treatment & Medication In:

animal model of multiple sclerosis. *Nat. Med*, Vol.11, pp. 328–334.

mice are ligand selected. *J Exp Med*, Vol.173, pp. 1357-1371.

Syndrome Trial Group. *Ann Neurol,* Vol.44, No.5, pp. 780-788.

demyelinating polyneuropathy. *Ann Neurol,* Vol.39, pp. 625–635.

Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. *Brain,* 

multiple sclerosis: retinal atrophy and inflammation irrespective of disease

& Becher, B. (2005). Dendritic cells permit immune invasion of the CNS in an

Swan, A.V. (1998). Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre

(1996). Immune attack on the Schwann cell surface in acute inflammatory

M., Sarkar, N., Agarwal, S., Langer-Gould, A. & Smith, C.H. (2008) B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. *N Engl J Med*, Vol.358,

plasma exchange and immunoadsorption therapy in a case of stiff-man syndrome

*emedicine,*16.03.2011,Available from URL: emedicine.medscape.com/article/315632-

Weinstock-Guttman, B., Munschauer, F. & Sternberg, Z. (2011). Plasma pentosidine: A potential biomarker in the management of multiple sclerosis. *Multiple Sclerosis,* 

Rulicke, T., Prinz, M., Priller, J., Becher, B. & Aguzzi, A. (2005). Experimental autoimmune encephalomyelitis repressed by microglial paralysis. *Nat Med*, Vol.11,

*Nature*, Vol.402, pp. 255-262.

duration, *Brain,* Vol.133, pp. 1591–1601.

Vol.24, pp. 1138–1148.

1838–1841.

treatment.

No.7, pp. 676–688.

Vol.17, No.2, pp. 157-163

*Clin North Am,* Vol*.*26, No.4, pp. 737-763.

system. *J. Neurosci. Res*, Vol.28, pp. 254–260.

function. *Curr Opin Immunol,* Vol.7, pp. 121-129.

No.2, pp. 146–152.


Recent Advances in the Treatment of Neurological Autoimmune Disorders 317

Lennon, V.A., Kryzer, T.J., Pittock, S.J., Verkman A.S. & Hinson, S.R. (2005). IgG marker of

Leung, E., Kanwar, R.K., Kanwar, J.R. & Krissansen, G.W. (2003). Mucosal vascular

fibroblasts and melanoma cells. *Immunol Cell Biol*, Vol.81, No.4, pp. 320-327. Lim, K.J.H., Odukoya, O.A. & Ajjan, R.A. (1998). Profile of cytokine mRNA expression in peri-implantation human endometrium. *Mol.Hum. Reprod*, Vol.4, pp. 77–81. Lleo, A., Invernizzi, P., Gao, B., Podda, M. & Gershwin, M.E. (2010). Definition of human

Lucchinetti, C., Bruck, W., Parisi, J., Scheithauer, B., Rodriguez, M. & Lassmann, H. (2000).

Lucchinetti, C.F., Mandler, R.N., McGavern, D., Bruck, W., Gleich, G. & Ransohoff R.M.

Lutterotti, A. & Berger, T. (2010). Advances in Multiple Sclerosis Therapy: New Oral Disease-Modifying Agents, *CML – Multiple Sclerosis,* Vol.2, No.1, pp. 1–10. Mackay, C. R., Marston, W. L. & Dudler, L. (1990). Naive and memory T cells show distinct

Manoury, B, Hewitt, E.W, Morrice, N, Dando, P.M, Barrett, A.J. & Watts, C. (1998). An

Manz, R.A., Thiel, A. & Radbruch, A. (1997). Lifetime of plasma cells in the bone

 Manz, R.A., Löhning, M., Cassese, G., Thiel, A. & Radbruch, A. (1998). Survival of longlived plasma cells is independent of antigen. *Int. Immunol,* Vol.10, pp. 1703–1711. Manz, R.A., Hauser, A.E., Hiepe, F. & Radbruch, A. (2005). Maintenance of serum antibody

Marmont, A.M. (2000). New horizons in the treatment of autoimmune diseases: immunoablation and stem cell transplantation. *Annu Rev Med*, Vol.51, pp. 115-134. Maverakis, E., Goodarzi, H., Wehrli, L.N., Ono, Y. & Garcia, M.S. (2011). The Etiology of

*McEvoy, K.M., Windebank, A.J., Daube, J.R. & Low, PA. (1989). 3,4-Diaminopyridine in the* 

McKall-Faienza, K.J., Kawai, K., Kundig, T.M., Odermatt, B., Bachmann, M.F., Zakarian, A.,

Paraneoplastic Autoimmunity. *Clin Rev Allergy Immunol*, Jan 19 [Epub ahead of

*treatment of Lambert-Eaton myasthenic syndrome.* N Engl J Med*,* Vol.321, No.23, pp*.* 

Mak, T.W. & Ohashi, P.S. (1998). Absence of TNFRp55 influences virus-induced autoimmunity despite efficient lymphocytic infiltration. *Int Immunol,* Vol.10, pp.

Vol.202, pp. 473–477.

*Reviews,* Vol.9, pp. 259–266.

340-350.

print].

1567-1571.

405-412.

demyelination. *Ann Neurol*, Vol.47, pp. 707–717.

optica, *Brain,* Vol.125, pp. 1450–1461.

presentation. *Nature,* Vol.396, pp. 695–699.

levels. *Annu. Rev. Immunol,* Vol*.*23, pp. 367–386.

MayoClinic, *Multiple Sclerosis,* 25.02.2011*,* Available from URL:

www.mayoclinic.org/multiple-sclerosis/

marrow.*Nature,* Vol.388, pp. 133–134.

optic-spinal multiple sclerosis binds to the aquaporin-4 water channel, *J Exp Med,* 

addressin cell adhesion molecule-1 is expressed outside the endothelial lineage on

autoimmunity — autoantibodies versus autoimmune disease. *Autoimmunity* 

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of

(2002). A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis

pathways of lymphocyte recirculation. *J. Exp. Med*, Vol. 171, No.3, pp. 801-817*.*  Mackay, R. & Rosen, F.S. (2001). Autoimmune Diseases. *N Engl J Med*, Vol.345, pp.

asparaginyl endopeptidase processes a microbial antigen for class II MHC


Kanwar, J.R, Kanwar, R.K., Burrow, H. & Baratchi, S. (2009). Recent advances on the roles of

Kanwar, J.R., Kamalapuram, S.K. & Kanwar, R.K. (2010a). Targeting survivin in cancer:

Kanwar, J.R, Mahidhara, G. & Kanwar, R.K. (2010b). MicroRNA in human cancer and chronic inflammatory diseases. *Front Biosci (Schol Ed,* Vol*.*1, No.2, pp. 1113-1126. Kanwar, J.R., Mohan, R.R., Kanwar, R.K., Roy, K. & Bawa, R. (2010c). Applications of

Kanwar, R.K., Cheung, C.H., Chang, J.Y. & Kanwar, J.R. (2010d). Recent advances in antisurvivin treatments for cancer. *Curr Med Chem*, Vol.17, No.15, pp. 1509-1015. Kappler, J.W., Roehm, N. & Marrack, P. (1987). T cell tolerance by clonal elimination in the

Kauppinen, S., Vester, B. & Wengel, J. (2005). Locked nucleic acid (LNA): High affinity

Keefe, D., Parng, C., Lundberg, D., Ray, S., Martineau-Bosco, J., Leng, C., Tzartos, S., Powell,

Khamashta, M.A., Ruiz-Irastorza, G. & Hughes, G.R. (1997). Systemic lupus erythematosus

Kieseier, B.C., Kiefer, R., Gold, R., Hemmer, B., Willison, H.J. & Hartung, H. P. (2004).

Kleopas, A.K., Elman, L.B., Lang, B., Vincent, A. & Scherer, S.S. (2006). Neuromyotonia and

Kornberg, A.J. & Pestronk, A. (2003). Antibody-associated polyneuropathy syndromes:

Koski, C.L. & Patterson, J.V. (2006). Intravenous immunoglobulin use for neurologic

Kumar, V. & Kaminski, H.J. (2011). Treatment of Myasthenia Gravis. *Curr Neurol Neurosci* 

Kuwabara, S. (2004). Guillain-Barré syndrome: epidemiology, pathophysiology and

Lai, M., Huijbers, M.G.M., Lancaster, E., Graus, F., Bataller, L., Balice-Gordon, R., Cowell,

Lambert-Eaton syndrome, In: *PubMed Health*,09.03.2011,Available from URL:

J.K. & Dalmau, J. (2010). Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: A case series *The Lancet Neurology*,

flares during pregnancy. *Rheum. Dis. Clin. N. Am*, Vol.*23*, pp. 15–30.

correlates with clinical manifestations. *Brain*, Vol.129, pp. 1570–1584. Knopf, P. M., Harling-Berg, C. J., Cserr, H. F., Basu, D., Sirulnick, E. J. & Nolan, S. C. (1998).

myasthenia gravis. *Autoimmunity,* Vol.43, No.8, pp. 628–639.

peripheral nervous system. *Muscle Nerve*, Vol.30, pp. 131–156.

principles and treatment. *Semin Neurol*, Vol.23, pp. 181–190.

www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001729/.

diseases. *J Infus Nurs*, Vol.29, Suppl.3, pp. S21-8.

management. *Drugs,* Vol.64, pp. 597–610.

*Rep*, Vol.11, pp. 89–96.

Vol.9, No.8, pp. 776-785.

patent review. *Expert Opin Ther Pat*, Vol.20, No.12, pp. 1723-37.

*Nanomedicine*,Vol.5, No.9, pp. 1435-45.

thymus. *Cell,* Vol.49, pp. 273–280.

*Today: Technol*, Vol.2, pp. 287.

pp. 2373-2394.

NO in cancer and chronic inflammatory disorders. *Curr Med Chem*, Vol.16, No.19,

aptamers in nanodelivery systems in cancer, eye and inflammatory diseases.

targeting of Complementary RNA for diagnostics and therapeutics. *Drug Discovery* 

J., Concino, M., Heartlein, M., Lamsa, J. & Josiah, S. (2010). In vitro characterization of an acetylcholine receptor–transferrin fusion protein for the treatment of

Advances in understanding and treatment of immune-mediated disorders of the

limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity

Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells. *J Immunol,* Vol.161, pp. 692–701.


Recent Advances in the Treatment of Neurological Autoimmune Disorders 319

Pircher, H., Rohrer, H.U., Moskophidis, D., Zinkernagel, R.M. & Hengartner, H. (1991).

Polman, C.H., O'Connor, P.W., Havrdova, E., Hutchinson, M., Kappos, L. & Miller, D.H*.*

Pranzatelli, M.R., Travelstead, A.L., Tate, E.D., Allison, T.J., Moticka, E.J., Franz, D.N.,

Qin, Y., Duquette, P., Zhang, Y., Talbot, P., Poole, R. & Antel, J. (1998). Clonal expansion and

Quarles, R.H. & Weiss, M.D. (1999). Autoantibodies associated with peripheral neuropathy.

Racke, M.K & Stuart, R.W. (2002). Targeting T cell costimulation in autoimmune disease.

Radbruch, A., Muehlinghaus, G., Luger, E.O., Inamine, A., Smith, K.G., Dörner, T. & Hiepe,

Ragheb. & Lisak, R.P. (1998). Immune regulation and myasthenia gravis. *Ann N Y Acad Sci,* 

Raghupathy, R. (1997). Th–1 type immunity is incompatible with successful pregnancy.

Rajewsky, K. (1996). Clonal selection and learning in the antibody system. *Nature,* Vol.381,

Rodien, P., Madec, A.M., Ruf, J., Rajas, F., Bornet, H. & Carayon, P. (1996). Antibody-

Rosenfeld, M.R., Eichen, J.G., Wade, D.F., Posner, J.B. & Dalmau, J. (2001). Molecular and

Ross, R. (1990). Mechanisms of atherosclerosis-a review. *Adv Nephrol Necker Hosp*,Vol.19,

Galperin, C & Gershwin, ME. (1997). Immunopathogenesis of gastrointestinal and

Roubinian, J.R., Talal, N., Greenspan, J.S., Goodman, J.R. & Siiteri, P.K. (1978).Effect of

Roitt, I, Brostoff, J & Male, D. (1998). Immunology, Mosby, London UK, pp. 410- 425.

hepatobiliary diseases. *JAMA*,Vol.278, pp. 1946-1955.

MRL/lpr mice. *J Neuroimmunol,* Vol.87, pp. 162-170.

function. *Nature,* Vol.351, pp. 482–485.

*Neurology,* Vol.62, pp. 1526–1532.

*Muscle Nerve*, Vol.22, pp. 800–822.

*Immunol. Today*, Vol.18, pp. 478–482.

Vol.841, pp. 210–224.

pp.(751–758).

pp. 339–348.

pp.79-86.

sclerosis. *J Clin Invest*, Vol.102, pp. 1045–1050.

*Expert Opin Ther Targets,* Vol.6, No.3, pp. 275-89.

plasma cell. *Nat. Rev. Immunol,* Vol.6, pp. 741–750.

multiple sclerosis. *N Engl J Med, Vol.*354, pp. 899–910.

Lower receptor avidity required for thymic clonal deletion than for effector T cell

(2006). A randomized, placebo-controlled trial of natalizumab for relapsing

Nigro, M.A., Parke, J.T., Stumpf, D.A. & Verhulst, S.J. (2004). B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes,

somatic hypermutation of VH genes of B cells from cerebrospinal fluid in multiple

F*.* (2006). Competence and competition: the challenge of becoming a long-lived

dependent cell-mediated cytotoxicity in autoimmune thyroid disease: relationship to antithyroperoxidase antibodies. *J Clin Endocrinol Metab,* Vol.81, pp. 2595–2600.

clinical diversity in Paraneoplastic immunity to Ma proteins. *Ann Neurol,* Vol.50,

castration and sex hormone treatment on survival,anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. *J Exp Med*, Vol.147, pp. 1568-1583. Ruegg, S.J., Fuhr, P. & Steck, A.J. (2004). Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. *Neurology,* Vol.63, pp. 2178–2179. Sakic, B., Szechtman, H., Denburg, J.A., Gomy, G., Kolb, B. & Whishaw IQ.

(1998).Progressive atrophy of pyramidal neuron dendrites in autoimmune


www.merckmanuals.com/home/sec06/ch092/ch092b.html


McMurray, R.W. (1996). Adhesion molecules in autoimmune disease. *Semin Arthritis Rheum,* 

Merchut, M.P. (2010). Management of voltage-gated potassium channel antibody disorders.

Mertens, H.G., Hertel, G., Reuther, P. & Ricker, K. (1981). Effect of immunosuppressive

Monroe, J.G., Bannish, G., Fuentes-Panana, E.M., King, L.B., Sandel, P.C., Chung, J. & Sater,

Moreno, B., Fernandez-Diez, B., Di Penta, A. & Villoslada, P. (2010). Preclinical studies of

Muramatsu, T. (2011). Midkine: a Promising Molecule for Drug Development to Treat

Latov, N. (1994). Antibodies to glycoconjugates in neuropathy and motor neuron disease.

Ogawara, K., Kuwabara, S., Mori, M., Hattori, T., Koga, M. & Yuki, N. (2000). Axonal

Campylobacter jejuni infection in Japan. *Ann Neurol,* Vol.48, pp. 624–631. Ohishi, K., Kanoh, M., Shinomiya, H., Hitsumoto, Y. & Utsumi, S. (1995). Complement

Oldstone, M.B.A. (1998). Molecular mimicry and immune-mediated diseases. *FASEB J,* 

Osborne, R. (2009). Buzz around Campath proof-of-concept trial in MS. *Nat Biotechnol*,

Palmer, E. (2003). Negative selection – clearing out the bad apples from the T-cell repertoire.

Patterson, C.C., Carson, D.J. & Hadden, D.R. (1996). Epidemiology of childhood IDDM in

Pender, M.P. (1995). An introduction to neuroimmunology, In: *Autoimmune neurological diseases,*Pender, M.P & McCombe, P.A, pp.16. cambridge university press. Peterson, K., Rosenblum, M.K., Kotanides, H. & Posner, J.B. (1992). Paraneoplastic cerebellar

Pettinelli, C.B. & McFarlin, D.E. (1981). Adoptive transfer of experimental allergic

and most household crowding. *Diabetologia*, Vol.39, pp. 1063-1069.

R. (2003). Positive and negative selection during B lymphocyte development.

methylthioadenosine for the treatment of multiple sclerosis. *Mult Scler,* Vol.16,

Diseases of the Central Nervous System. *Curr Pharm Des,* Mar 4. [Epub ahead of print]. *Multiple Sclerosis Treatments,* 27.02.2011*,* Available from URL: www.multsclerosis.org/mstreatments.html Nobile-Orazio, E. (2001). Multifocal motor

Guillain-Barré syndrome: relation to anti-ganglioside antibodies and

activation by cross-linked B cell-membrane IgM. *J Immunol*, Vol.154, pp. 3173–3179.

Northern Ireland 1989e1994: low incidence in areas with highest population density

degeneration: I. A clinical analysis of 55 anti-Yo antibody positive patients,

encephalomyelitis in SJL/J mice after in vivo activation of lymph node cells by myelin basic protein: requirement for Lyt-1+2- T lymphocytes. *J Immunol*, Vol.127,

drugs (azathioprine). *Ann NY Acad Sci,* Vol.377, pp. 691-699.

Vol.25, No.4, pp. 215-33.

*Neurologic Clinics*, Vol.28, No.4, pp. 941-959. Merck, *Multiple Sclerosis (MS),* 27.02.2011, Available from URL: www.merckmanuals.com/home/sec06/ch092/ch092b.html

neuropathy. *J Neuroimmunol*, Vol.115, pp. 4–18.

*Prog Brain Res*, Vol.101, pp. 295–303.

*Nat. Rev. Immunol,* Vol.3, pp. 383–391.

*Neurology,* Vol.42, pp. 1931–1937.

*Immunol. Res,* Vol.27, pp. 427–442.

No.9, pp. 1102-1108.

Vol.12, pp. 1255–1265.

Vol.27, No.1, pp. 6–8.

pp. 1420-1423.


Recent Advances in the Treatment of Neurological Autoimmune Disorders 321

Vandiedonck, C., Capdevielle, C., Giraud, M., Krumeich, S. & Jais, J.P. (2006). Association of

VanVoorhis, B.J. & Stovall, D.W. (1997). Autoantibodies and fertility: a review of the

Vincent, A., Beeson, D. & Lang, B. (2000). Molecular targets for autoimmune and genetic disorders of neuromuscular transmission. *Eur J Biochem,* Vol.267, pp. 6717–6728. Vincent, A., Bowen, J., Newsom-Davis, J. & McConville, J. (2003). Seronegative generalised

Vogt, M.H., Lopatinskaya, L., Smits, M., Polman, C.H. & Nagelkerken, L. (2003). Elevated

Waldor, M.K., Sriram, S., Hardy, R., Herzenberg, L.A., Herzenberg, L.A., Lanier, L., Lim, M.

Warnke, C., Meyer, H.G., Hartung, H.P., Stuve, O. & Kieseier, B.C. (2009). Review of

Webster, E.L., Torpy, D.J., Elenkov, I.J. & Chrousos, G.P. (1998). Corticotropinreleasing

Wekerle, H., Linington, C., Lassmann, H. & Meyermann, R, (1986). Cellular immune

Whitaker, J.N. (1987). The presence of immunoreactive myelin basic protein peptide in urine of persons with multiple sclerosis. *Ann Neurol*, Vol.22, No.5, pp. 648–655. Willison, H. J. & Yuki, N. (2002). Peripheral neuropathies and anti-glycolipid antibodies.

Wingerchuk, D.M. (2004). Neuromyelitis optica: current concepts, *Front Biosci,* Vol.9, pp.

www.wipo.int/pctdb/en/fetch.jsp?LANG=ENG&DBSELECT=PCT&SERVER\_TY

ULT=5&TOTAL=7&START=1&DISP=25&FORM=SEP-0/HITNUM,B-

Wylam, M.E., Anderson, P.M., Kuntz, N.L. & Rodriguez, V. (2003). Successful treatment of

Wynne, A., Kanwar, R.K., Khanna, R. & Kanwar, J.R. (2010). Recent Advances on the

KEY&TYPE\_FIELD=256&IDB=0&IDOC=1324445&C=10&ELEMENT\_SET=B&RES

ENG&SEARCH\_IA=US2001032198&QUERY=%28PA%2fJagat+AND+PA%2fKanw

refractory myasthenia gravis using rituximab: a pediatric case report. *J Pediatr,*

Possible Neuroprotective Activities of Epstein- Barr Virus Oncogene BARF1 Protein in Chronic Inflammatory Disorders of Central Nervous System. *Current* 

Syndrome. *Expert Opin Emerg Drugs*, Vol.16, No.1, pp. 105-120.

hormone and inflammation. *Ann NY Acad Sci,* Vol.840, pp. 21-32.

reactivity within the CNS. *Trends Neurosci*, Vol.9, pp. 271–277.

*Neuro, .*Vol*.*59, pp. 404–407.

Vol.2, pp. 99-106.

Vol.53, No.6, pp. 819–822.

*Dis Treat,* Vol.5, pp. 333–340.

*Brain,* Vol.125, pp. 2591–2625.

WIPO, 28.03.2011, Available from URL:

Vol.143, pp. 674–677.

PE=19-10&SORT=11316447-

ENG,DP,MC,AN,PA,ABSUM-

*Neuropharmacology*, Vol.8, pp. 268-275.

834–840.

ar%29+]

literature. *J. Reprod. Immunol.*Vol.33, pp. 239–256.

the PTPN22∗R620W polymorphism with autoimmune myasthenia gravis. *Ann.* 

myasthenia gravis: clinical features, antibodies and their targets. *Lancet Neurol,* 

osteopontin levels in active relapsing–remitting multiple sclerosis. *Ann Neurol,* 

& Steinman, L. (1985). Reversal of experimental allergic encephalomyelitis with a monoclonal antibody to a T cell subset marker (L3T4). *Science*, Vol.15, pp. 417 Walgaard, C., Jacobs, B.C. & Van Doorn, P.A. (2011). Emerging drugs for Guillain-Barr?

teriflunomide and its potential in the treatment of multiple sclerosis. *Neuropsychiatr* 


Sanders, D.B. (1995). Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-

Schattner, A. (1994). Lymphokines in autoimmunity-a critical review. *Clin Immunol* 

Schneider-Gold, C., Hartung, H.P. & Gold, R. (2006). Mycophenolate mofetil and tacrolimus:

Shy, M.E. (2007). Peripheral neuropathies, Goldman L, Ausiello D. In: *Cecil Medicine,*

Silverstein, A.M. & Rose, N.R. (2000).There is only one immune system! The view from immunopathology. *Semin Immunol*, Vol.12, No.173, No.8, pp. 257-344. Singer, P.A. & Theofilopoulos, A.N. (1990).T cell receptor V) repertoire expression in murine

Slifka, M.K., Antia, R., whitmire, J.K. & Ahmed, R. (1998). Humoral immunity due to long-

Smith, D.A. & Dori, R. (1999). Introduction to Immunology and Autoimmunity. *Environmental Health Perspectives,* Vol.107, Supplement. 5, pp. 661-665. Starr, T.K., Jameson, S.C. & Hogquist, K.A. (2003). Positive and negative selection of T cells.

Steinman, L. (2002). A few autoreactive cells in an autoimmune infiltrate control a vast

Stohl, S.W. (2004). Targeting B lymphocyte stimulator in systemic lupus erythematosus and

Stojanovich, L. & Marisavljevich, D. (2008). Stress as a trigger of autoimmune disease

Stuve, O., Cepok, S., Elias, S., Saleh, A., Hartung, H.P., Hemmer, B. *&* Kieseier, B.C. (2005).

Swain, S.L. (2003). Regulation of the generation and maintenance of T-cell memory: a direct,

Tan, M.E., Reimer, G. & sullivan, K.(1987).Itracellularv antigens:diagnostic fingerprints but

Tarlinton, D., Radbruch, A., Hiepe, F. & Dörner, T. (2008). Plasma cell differentiation and

Tindall, R.S., Rollins, J.A., Phillips, J.T., Greenlee, R.G., Wells, L. & Belendiuk, G. (1987).

cyclosporine in myasthenia gravis. *N Engl J Med,* Vol.316, pp. 719-724. Trembleau, S., Germann, T., Gately, M.K. Z. & Adorini, L. (1995).The role of IL-12 in the

population of nonspecific cells: a tale of smart bombs and the infantry. *Proc. Natl.* 

other autoimmune rheumatic disorders. *Expert Opin Ther Targets*, Vol.8, pp. 177–

Clinical stabilization and effective bB-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing–remitting multiple

default pathway from effectors to memory cells. *Microbes. Infect,* Vol.5, pp. 213–219

aetiological dilemmas, Evered, D & Whelan, J. In: *autoimmunity and autoimmune* 

Preliminary results of a double-blind, randomized, placebo-controlled trial of

induction of organ-specific autoimmune diseases. *Immunol Today*, Vol.16, pp. 383-

63-73.

pp.284-291.

189.

386.

*Immunopathol,* Vol.70, pp. 177-189.

Elsevier, Philadelphia, Pa: Saunders, pp.446.

models of SLE. *Immunol Rev,* Vol.118, pp. 103-127.

lived plasma cells. *Immunity*, Vol.8, pp. 363–372.

*Annu. Rev. Immunol,* Vol.21, pp. 139–176.

*Acad. Sci. U. S. A,* Vol.93, pp. 2253–2256.

*Autoimmun Rev*, Vol.7, No.3, pp. 209-213.

sclerosis, *Arch Neurol*, Vol.62, pp. 1620–1623.

*disease.* John Wiley & Sons Ltd, Chichester,UK, pp. 25-30.

survival. *Curr.Opin. Immunol*, Vol*.*20, pp. 162–169.

mediated mechanisms, and update on therapies. *Ann Neurol*, Vol.37, Suppl 1, pp.

New therapeutic options in neuroimmunological diseases. *Muscle & Nerve,* Vol.34,


 www.wipo.int/pctdb/en/fetch.jsp?LANG=ENG&DBSELECT=PCT&SERVER\_TY PE=19-10&SORT=11316447-

KEY&TYPE\_FIELD=256&IDB=0&IDOC=1324445&C=10&ELEMENT\_SET=B&RES ULT=5&TOTAL=7&START=1&DISP=25&FORM=SEP-0/HITNUM,B-

ENG,DP,MC,AN,PA,ABSUM-ENG&SEARCH\_IA=US2001032198&QUERY=%28PA%2fJagat+AND+PA%2fKanw ar%29+]


Yagi, J. & Janeway, C.A. (1990). Ligand thresholds at different stages of T cell development. *Int. Immunol,* Vol.2, pp. 83–89.

**16** 

*Mexico* 

**Synthetic Glucocorticoids Modulate Function of** 

Oscar Gonzalez-Perez, Norma A. Moy-Lopez and Jorge Guzman-Muniz

Glucocorticoids are hormones synthesized from cholesterol in the cortex of adrenal glands. Synthetic glucocorticoids are chemical derivatives synthesized from cholic acid obtained from cattle or steroid sapogenins. The chemical structure of these drugs is very similar to that of natural glucocorticoids. Therefore, the synthetic derivatives efficiently bind to intracellular receptors of glucocorticoid and mineralocorticoid, which promote a myriad of transcriptional and non-transcriptional processes. Synthetic glucocorticoids can trigger a cascade of events including neurotransmitter modulation, protein expression, neuronal firing or neurite growth. In addition, these substances are some of the most potent antiinflammatory and immunosuppressive agents available in human medicine with a good drug safety profile in humans. Thus, they are a valuable pharmacological tool for the treatment of acute and chronic neuroinflammation, and autoimmune disorders with neurological involvement. However, increasing evidence indicates that a high-dose or a long-term delivery of synthetic glucocorticoids may promote cognitive dysfunction, memory impairment, apoptosis, systemic hypersensitivity, urticaria-angioedema, neuronal degeneration, cerebral atrophy, major depression or steroid psychosis. Yet, these major side effects are relatively infrequent, the unrestricted use of glucocorticoids has to be avoided and systematic neuropsychological assessments are recommended to detect early neurological impairment. Herein, we discuss the mechanisms by which synthetic glucocorticoids may induce neural degeneration and other pathological changes in different brain regions. In addition, we describe the role of glucocorticoids in some autoimmune

The hypothalamus-pituitary-adrenal axis exerts an important regulation on neural functions mediated by the releasing of steroid molecules named corticosteroids. These hormones are synthesized from cholesterol in the cortex of adrenal glands (Fietta et al., 2009; Nicolaides et al., 2010). Two types of corticoids have been identified: glucocorticoids and mineralocorticoids. Glucocorticoids are produced in the inner region of the adrenal cortex (fascicular zone), while mineralocorticoids are synthesized in the outer part of the adrenal

**1. Introduction** 

neurological disorders.

**2. Glucocorticoids** 

**Neural Cells: Implications in Autoimmune** 

*University of Colima/ Laboratory of Neuroscience, School of Psychology* 

**Neurological Disorders** 

